The availability of a new therapy is often the primary driver for diagnostic adoption. For Lynch syndrome, many at-risk individuals don't get tested because there's no preventative treatment. Newscom believes its therapy will create a strong incentive for genetic testing, mirroring how checkpoint inhibitors drove a 5x increase in MSI screening.

A dual-biomarker approach may revolutionize bladder cancer monitoring. Experts suggest urinary tumor DNA (utDNA) is superior for assessing the local tumor in the bladder wall, while circulating tumor DNA (ctDNA) monitors systemic disease. A negative result on both tests could provide the confidence needed to safely skip radical cystectomy.

Personalized, tumor-informed ctDNA approaches (like Signatera) are more specific and sensitive for bladder cancer than general panel-based assays. This is because bladder cancer has a distinct mutational landscape and because panel approaches can yield false positives from clonal hematopoiesis, making the personalized technique essential for accurate results in this disease.

Despite NCCN guidelines placing POLE testing first in the hierarchy, many US institutions do not perform it routinely because it currently does not alter standard-of-care treatment. Clinicians often only order the send-out test when a specific clinical trial (like RAINBO) requires it to de-escalate care.

While most MMR-deficient patients don't have Lynch syndrome, the biomarker is a crucial screening tool for this hereditary cancer condition. This finding has significant implications for both the patient and their family's health through cascade genetic testing.

Experts suggest urinary tumor DNA (utDNA) may better reflect local disease in the bladder, while circulating tumor DNA (ctDNA) indicates systemic disease. Using both tests in parallel could provide a more complete picture, with dual-negative results potentially becoming a key criterion for safely pursuing bladder-sparing approaches.

A positive ctDNA (blood) but negative utDNA (urine) test suggests systemic, metastatic disease. Conversely, a positive utDNA with negative ctDNA points to a tumor confined to the bladder. This integrated biomarker approach can help determine whether systemic therapy or local treatment like surgery is the priority.

While an approved option, systemic checkpoint inhibitors like pembrolizumab come with a significant downside. Clinicians counsel patients on a 15% chance of life-altering toxicities like permanent endocrine disease, a critical risk when the treatment often only delays, not prevents, cystectomy.

Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) offer complementary information. Used together, they provide superior risk stratification. Patients negative on both tests have a >70% chance of a complete pathological response, while those positive on both have only a ~5% chance, demonstrating clear additive value.